Junoenil (dimdazenil) / Evotec, Zhejiang Jingxin Pharma - LARVOL DELTA

Development and validation of an LC-MS/MS method for simultaneous determination of EVT201 and its five metabolites in human plasma: Application to a clinical study in Chinese healthy subjects. (PubMed, J Pharm Biomed Anal) - "Meanwhile, it is the first report to evaluate the pharmacokinetic characteristics of Ro40-9970, Ro66-9196 and Ro66-5448 in human plasma. It provided meaningful parameters for the safety and tolerability evaluation of EVT201 capsules in human."

Journal • CNS Disorders • Insomnia • Sleep Disorder

Development and validation of LC-MS/MS methods for the determination of EVT201 and its five metabolites in human urine: Application to a mass balance study. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "The methods were successfully applied to a mass balance study of EVT201. The results showed that the total cumulative urinary excretion rate of EVT201 and its five metabolites was 74.25 ± 6.50%, which suggested that EVT201 had high oral bioavailability, and urinary elimination was its major excretion pathway in human."

Journal • CNS Disorders • Insomnia • Sleep Disorder

Jingxin Pharmaceutical: EVT201 has now completed Phase III clinical enrollment, and clinical trial data is expected to be obtained by the end of October [Google translation] (Daily Economic News - NBD) - "Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform on October 20 that EVT201 has now completed Phase III clinical enrollment and is expected to obtain clinical trial data at the end of October."

Enrollment closed • P3 data • CNS Disorders • Insomnia • Sleep Disorder

Announcement of Zhejiang Jingxin Pharmaceutical Co., Ltd. on the progress of phase III clinical trials of EVT201 capsules [Google translation] (Sina Corp) - "Announcement on the progress of EVT201 capsule phase III clinical trial: Recently, the company has The notice of drug clinical trial requires the completion of preparations for the phase III clinical trial of EVT201 capsules and the successful implementation of clinical enrollment....As of the announcement date, two subjects have been successfully enrolled in phase III clinical trials. The company will continue to advance the phase III clinical trials of EVT201 capsules in an orderly manner."

Enrollment status • Trial status • CNS Disorders • Insomnia • Sleep Disorder